Last updated: April 23, 2026
Who Supplies Digoxin for the Pharmaceutical Market?
Digoxin is a widely used cardiac glycoside, supplied through (1) branded or branded-generics finished-dose manufacturers and (2) active pharmaceutical ingredient (API) producers. Sourcing is typically structured around approved finished products (tablets or injectable) and validated API supply for generic manufacturers.
What are the primary digoxin product forms and typical supplier categories?
Digoxin is sold as both finished dosage forms and as API for manufacturers.
Who supplies digoxin as finished dosage products?
Key suppliers are branded and generic finished-dose manufacturers that hold approvals for digoxin tablets and digoxin injection in specific countries. Finished products are the practical sourcing channel for hospitals, pharmacy wholesalers, and tenders.
| Supply channel |
What it provides |
Typical customer |
What to validate |
| Finished-dose manufacturers |
Approved tablets/injection |
Wholesalers, health systems, tender buyers |
Product authorization, labeling strength, batch release |
| Generic manufacturers |
Same active strength, bioequivalence |
Generic procurement |
Bioequivalence package and regulatory status |
| Local/national license holders |
Packaged product in-country |
Distributors, payers |
Import license and GMP dossier alignment |
Note: supplier identity is jurisdiction- and strength-dependent; digging into a specific tender or country procurement list is required for a definitive “supplier-by-name” roster.
Who supplies digoxin API (active ingredient)
API supply is typically provided by manufacturers of steroid glycosides and fermentation/extraction-based natural product derivatives. Digoxin API suppliers are often listed in:
- FDA drug application materials (for US generic and listed drug routes)
- EMA/EPAR and national dossier submissions (for European supply)
- ASMF holders (Active Substance Master File holders) supporting generic filings
Because API supply is not standardized globally and supplier identity varies by filing, supplier discovery usually occurs through:
- API specification in DMFs/ASMFs supporting market authorizations
- Vendor qualification lists of generic manufacturers
- Batch testing and GMP certification documentation from distributors
What supplier lists are commonly used in due diligence?
For digoxin, due diligence typically uses these artifacts rather than marketing claims:
- Regulatory status
- Drug product approval listings per jurisdiction
- Quality documents
- GMP certificates for the API or finished dosage site
- CoA (certificate of analysis) format and release testing parameters
- Regulatory support
- DMF (US) or ASMF (EU) referencing the manufacturing process and control strategy
- Technical specification
- Digoxin identity and purity profile (typical API controls include assay, related substances, water content where applicable, residual solvents if synthesis/extraction applies, and microbiological criteria as relevant)
What does “supplier” mean operationally for digoxin?
Procurement teams usually need supplier type clarity:
- For hospitals and wholesalers: finished-dose manufacturer or in-country license holder
- For generic manufacturers: API supplier (or API distributor) that supports the company’s validated process and regulatory filing package
- For tender bids: procurement unit may list brand and license holder rather than API origin
How to structure digoxin sourcing decisions
Given digoxin’s narrow therapeutic index, sourcing decisions usually hinge on batch-to-batch consistency and regulatory alignment.
| Decision point |
Operational driver |
What procurement checks |
| Product sourcing |
Formulation and strength availability |
Approved product listing by country |
| Quality release |
Consistency under specification |
CoA, impurity profile, method validation reference |
| Manufacturing continuity |
Supply risk |
Alternate pack sites, supply agreements, and contingency lots |
| Regulatory traceability |
Batch traceability |
Lot coding and distribution records |
Practical supplier discovery workflow used in industry
Even without a single universal supplier roster, the practical path to identify named suppliers is consistent:
- Start with jurisdiction-specific product approvals
- Build the list of authorized digoxin products for the country and strength
- Map license holders to manufacturers
- Identify the finished-dose site and responsible legal entity per application
- Trace the API route
- Use DMF/ASMF references in the regulatory package (where accessible) and manufacturer disclosures
- Qualify alternate supply
- Lock two sources when possible: one for primary volume and one for contingency
Key Takeaways
- Digoxin supply is split between finished-dose manufacturers (tablets/injection) and API suppliers supporting generic and branded manufacturers.
- Supplier naming is jurisdiction- and product-strength-specific; procurement usually relies on approved product listings and regulatory dossiers, not a global universal API vendor list.
- For digoxin’s narrow therapeutic index, sourcing due diligence centers on GMP site qualification, CoA testing against specification, and batch traceability.
- The fastest path to named suppliers is to identify authorized digoxin products in the target country and then trace manufacturing and API support through regulatory documentation.
FAQs
Which companies supply digoxin tablets and injection?
Companies differ by country and strength. Supplier identification is typically obtained from that jurisdiction’s approved drug product listings and tender award records.
How do procurement teams identify the digoxin API source?
They typically trace the regulatory dossier references (DMF/ASMF), then confirm via supplier qualification documentation and CoA/impurity profiles aligned to the filed specification.
Is digoxin supplied as API by the same firms that sell finished products?
Often separate supply chains exist: API manufacturers supply generic and branded formulators, while finished-dose firms hold product authorizations and distribute packaged product.
What quality attributes matter most when sourcing digoxin?
Assay and impurities (related substances), consistent dissolution/bioperformance for tablets, and release testing aligned to the regulatory specification.
What is the biggest sourcing risk for digoxin?
Supply continuity and batch-to-batch consistency under tight quality controls, driven by limited manufacturing capacity for certain API grades and by country-specific approvals.
References
[1] FDA. “Drugs@FDA: Digoxin.” U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] EMA. “European Medicines Agency (EMA) medicines: search results for digoxin.” European Medicines Agency. https://www.ema.europa.eu/
[3] DailyMed. “DIGOXIN (digoxin) drug label information.” U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
